- BioMarin’s adjusted earnings per share for the second quarter of 2025 were $1.44, surpassing analyst estimates of $1.06 and showing significant improvement from $0.96 year-over-year.
- Vimizim’s revenue reached $215 million, marking a 21% increase year-over-year and exceeding the estimate of $189.8 million.
- Naglazyme reported $129 million in revenue, slightly down by 2.3% year-over-year, but above the forecasted $119.6 million.
- Kuvan generated $27 million in revenue, a 5.6% decline year-over-year, yet surpassing projections of $21.8 million.
- Palynziq’s revenue was $106 million, showing a 20% increase year-over-year, above the $100.6 million estimate.
- Brineura’s revenue was $49 million, growing by 8.2% year-over-year, exceeding the expected $45.5 million.
- Voxzogo’s revenue came in at $221 million, which is a 20% increase year-over-year and higher than the estimate of $218.4 million.
- Aldurazyme’s revenue increased by 45% to $56 million, significantly above the $43.5 million estimate.
- Total revenue for BioMarin in the quarter was $825 million, which represents a 16% increase year-over-year and was ahead of the $762.6 million forecast.
- The company’s total enzyme therapies revenues are expected to remain strong in the second half of 2025, despite usual variations in quarterly order timing.
- Strong global demand for BioMarin’s innovative therapies resulted in notable revenue growth and profitability expansion.
- The stock has 23 buy ratings, 6 hold ratings, and no sell ratings from analysts at this time.
Biomarin Pharmaceutical on Smartkarma
Analyst coverage of Biomarin Pharmaceutical on Smartkarma highlights positive sentiments from research reports by Baptista Research. In one report titled “BioMarin Pharmaceutical: Expanding VOXZOGO Market Penetration To Up Their Game!“, the company’s strong first-quarter financial results for 2025 were emphasized. Notably, Biomarin reported a 15% increase in total revenue to $745 million, with VOXZOGO contributing significantly to this growth by generating $214 million, a 40% year-over-year increase. The enzyme therapies business unit also saw growth, boosted by a 22% increase in PALYNZIQ revenues.
Another report by Baptista Research titled “BioMarin Pharmaceutical: Expansion of VOXZOGO & Enzyme Replacement Therapy Growth Propelling Our ‘Buy’ Rating!” further reinforces the positive outlook. The report lauds Biomarin’s strong financial results for the fourth quarter and full year of 2024, noting an impressive 18% year-over-year revenue growth to $2.85 billion. The success was largely attributed to the performance of VOXZOGO for achondroplasia, which saw a 56% increase in revenue year-over-year. These reports indicate a bullish sentiment towards Biomarin Pharmaceutical‘s growth prospects and market performance.
A look at Biomarin Pharmaceutical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Biomarin Pharmaceutical shows a promising long-term outlook. With a high Growth score of 5 and a solid Resilience score of 4, the company is positioned well for future expansion and able to weather challenges effectively. This indicates that Biomarin Pharmaceutical has strong potential for advancement and the ability to withstand market fluctuations.
Although Biomarin Pharmaceutical scores lower in terms of Dividend at 1, its overall outlook remains positive due to its competitive Value score of 3 and moderate Momentum score of 3. Investors may find Biomarin Pharmaceutical to be an attractive prospect for long-term investment, given its strengths in growth and resilience according to the Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
